Back to Authors

Krumsiek, Jan

0000-0003-4734-3791

Mayo Clinic

Department of Systems and Computational Biomedicine (J.C.-B., J.K.), Weill Cornell Medical College, New York, NY.

Citations 2

Metabolomics of Right Ventricular Function in Pulmonary Hypertension
Chacon-Barahona, Jonathan , Chung, Samuel J. , Garry, Jonah , Frantz, Robert P. , Hassoun, Paul M. , Mathai, Stephen C. , Simpson, Catherine E. , Beck, Gerald, Hill, Nicholas S. , MUKHERJEE, MONICA, Jacob, Miriam , Park, M H, Finet, J Emanuel, Farha, Samar , Grünig, Gabriele , Kwon, Deborah, Comhair, Suzy , Erzurum, Serpil, Barnard, John, Jellis, Christine , Racanelli, Alexandra Christin, Krumsiek, Jan , hemnes, anna, Horn, Evelyn, Group, on behalf of the PVDOMICS Study, Beck, Gerald J. , Garry, Jonah D , Hassoun, Paul M , Mathai, Stephen C , Simpson, Catherine E , Beck, Gerald J , Hill, Nicholas S , Leopold, Jane A , Waxman, Aaron B. , Rosenzweig, Erika B , Borlaug, Barry A , Mukherjee, Monica , Vanderpool, Rebecca R , Jacob, Miriam , Mehra, Reena , Park, Margaret M , Finet, J Emanuel , Kwon, Deborah H , Comhair, Suzy , Erzurum, Serpil C , Barnard, John , Hu, Bo , Jellis, Christine L , Krumsiek, Jan , Brittain, Evan L , Hemnes, Anna , Horn, Evelyn M , Frantz, Robert P , Chacon-Barahona, Jonathan , Chung, Samuel J. , Rischard, Franz , Leopold, Jane A. , Rosenzweig, Erika B. , Borlaug, Barry A. , Mukherjee, Monica , Vanderpool, Rebecca , Mehra, Reena , Finet, J. Emanuel , Erzurum, Serpil C. , Racanelli, Alexandra C. , Hemnes, Anna R. , Gro, on behalf of the PVDOMICS Study

Circulation Research | April 15, 2026 | Volume: 138 | Issue: 11 | Pages: No page available

10.1161/circresaha.125.327342 Get It

BACKGROUND: The metabolic mechanisms underlying right ventricular (RV) dysfunction are poorly understood, particularly outside of group 1 pulmonary hypertension (PH). We aimed to identify metabolites and pathways associated with RV systolic function and explored whether associations differed by pulmonary vascular resistance, PH group 1 status, and sex. METHODS: We analyzed data from the multicenter PVDOMICS (Pulmonary Vascular Disease Phenomics) cohort. RV systolic function metrics included fractional area change (echo), global longitudinal strain (echo), and ejection fraction (cardiac magnetic resonance). We used linear regression adjusted for age, sex, body mass index, and PH group to assess associations between metabolites and RV function. Pathway enrichment analyses were used to identify pathways significantly associated with RV function. Interaction terms were assessed to determine whether metabolite associations were modified by pulmonary vascular resistance, group 1 PH status, or sex. Least absolute shrinkage and selection operator regression was used to develop metabolite-based scores for RV function, and prognostic performance was assessed. RESULTS: There were 979 participants with plasma metabolomics and RV function data. Linear regression identified 170 metabolites that were significantly associated with all 3 RV metrics. Androgenic steroid, gamma-glutamyl amino acid, polyamine, vitamin A, fatty acid, and sterol pathways are most strongly associated with RV systolic function. Two metabolites interacted with group 1 PH status, and 6 interacted with pulmonary vascular resistance. Four androgenic steroids are associated more strongly with RV systolic function in women compared with men. Metabolite-based scores were prognostically equivalent to RV systolic function metrics and less accurate than REVEAL Lite 2 scores. CONCLUSIONS: We provide a blueprint of metabolites and metabolic pathways associated with RV systolic function across the spectrum of PH. Novel links to vitamin A and glutathione metabolites were observed. We detected few metabolites that associated with RV systolic function differentially by group 1 PH status or degree of pulmonary vascular resistance elevation. Androgenic steroids may associate more strongly with RV systolic function in women compared with men.
The landscape of metabolic brain alterations in Alzheimer's disease
Batra, Richa , Arnold, Matthias , Wörheide, Maria A. , Allen, Mariet , Wang, Xue , Blach, Colette , Levey, Allan I. , Seyfried, Nicholas T. , Ertekin‐Taner, Nilüfer , Bennett, David A. , Krumsiek, Jan , Krumsiek, Jan , Bennett, David A. , Arnold, Matthias , Levey, Allan I , Kastenmüller, Gabi , Kaddurah‐Daouk, Rima

Alzheimer's & Dementia | July 13, 2022 | Volume: 19 | Issue: 3 | Pages: 980-998

10.1002/alz.12714 Get It

Abstract Introduction Alzheimer's disease (AD) is accompanied by metabolic alterations both in the periphery and the central nervous system. However, so far, a global view of AD‐associated metabolic changes in the brain has been missing. Methods We metabolically profiled 500 samples from the dorsolateral prefrontal cortex. Metabolite levels were correlated with eight clinical parameters, covering both late‐life cognitive performance and AD neuropathology measures. Results We observed widespread metabolic dysregulation associated with AD, spanning 298 metabolites from various AD‐relevant pathways. These included alterations to bioenergetics, cholesterol metabolism, neuroinflammation, and metabolic consequences of neurotransmitter ratio imbalances. Our findings further suggest impaired osmoregulation as a potential pathomechanism in AD. Finally, inspecting the interplay of proteinopathies provided evidence that metabolic associations were largely driven by tau pathology rather than amyloid beta pathology. Discussion This work provides a comprehensive reference map of metabolic brain changes in AD that lays the foundation for future mechanistic follow‐up studies.